Lantus Injection 100 Iu/ml 3 ml Cartridge

• Type 1 and 2 diabetes mellitus

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Lantus Injection 100 Iu/ml 3 ml   also causes some adverse impact on the body, most of which resolve without any medical attention.

Some common side effects include:

• Edema (swelling)
• Allergic reaction
• Injection site reactions (pain, swelling, redness)
• Rash
• Lipodystrophy (skin thickening or pits at the injection site)
• Itching
• Weight gain
• Hypoglycemia (low blood glucose level)

Seek medical attention in case of any unusual or severe side effects immediately.

• Dosage of the Lantus Injection 100 Iu/ml 3 ml decide according to the type of diabetes and overall health condition of the patient. This injection can be administered by a doctor or nurse or your care giver may be taught on how to use this medicine at home.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.

• Lantus Injection 100 Iu/ml 3 ml is a prescription based long-acting type of insulin. it helps to treat type 1 & type 2 diabetes by providing consistent and all-day sugar control. It works like the body's natural insulin.
• Insulin facilitates the reuptake of sugar in muscle and fat cells as well as suppresses sugar production in the liver.​
  

• Haque, M., Islam, S., Abubakar, A. R., Sani, I. H., Opanga, S., Kamal, Z. M., ... & Godman, B. (2021). Utilisation and expenditure on long-acting insulin analogues among selected middle-income countries with high patient co-payment levels: findings and implications for the future. Journal of Applied Pharmaceutical Science.
• Song, D., & Davidson, J. (2007). Cross-reactivity of Actrapid and three insulin analogues in the Abbott IMx insulin immunoassay. Annals of clinical biochemistry, 44(2), 197-198.
• Danne, T., Bangstad, H. J., Deeb, L., Jarosz‐Chobot, P., Mungaie, L., Saboo, B., ... & Hanas, R. (2014). Insulin treatment in children and adolescents with diabetes. Pediatric diabetes, 15.
• DeSouza, C., Cariou, B., Garg, S., Lausvig, N., Navarria, A., & Fonseca, V. (2020). Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. The Journal of Clinical Endocrinology & Metabolism, 105(2), 543-556.
• Haque, M., Islam, S., Kamal, Z. M., Akter, F., Jahan, I., Rahim, M. S. A., ... & Godman, B. (2021). Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications. Hospital practice, 49(4), 266-272.
• Nosrati, M., Ahmadi Fariman, S., Saiyarsarai, P., & Nikfar, S. (2023). Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran. Journal of Diabetes & Metabolic Disorders, 22(1), 817-825.
• Bhandarkar, A., Kumar, B. K., Praveen, V. P., & Chandramathi, J. (2025). Effective use of saline-diluted subcutaneous glargine in very low birth weight babies with neonatal hyperglycemia. Journal of Family Medicine and Primary Care, 14(8), 3542-3545.